Background: Recently, pretreatment monocyte counts and the lymphocyte/monocyte ratio (LMR) have been proven to be significantly associated with the clinical outcomes of several types of cancer. In this study, we analyzed the prognostic significance of the LMR in stage Ib1-IIa cervical cancer patients who underwent a radical operation.
Methods: A total of 485 patients with stage Ib1-IIa cervical cancer were included in this retrospective study. We evaluated the prognostic values of the absolute lymphocyte count, absolute monocyte count, and LMR by applying receiver operating characteristic curves. Kaplan-Meier curves and multivariate Cox proportional analyses were used to determine the recurrence-free survival (RFS) and overall survival (OS).
Results: The area under the curve was 0.640 for the RFS and 0.647 for the OS using the LMR. In the univariate analysis, an elevated preoperative LMR was significantly associated with an increased RFS (hazard ratio [HR], 0.373; 95% confidence interval [CI]: 0.247-0.563; P<0.001), and this result remained significant in the multivariate analysis (HR, 0.439; 95% CI: 0.279-0.693; P<0.001). In the univariate analysis, an elevated LMR was also significantly associated with an increased OS (HR, 0.381; 95% CI: 0.233-0.622; P<0.001), and the significance persisted in the multivariate analysis (HR, 0.417; 95% CI: 0.244-0.714; P=0.001).
Conclusion: A decreased pretreatment LMR is associated with a poor prognosis in stage Ib1-IIa cervical cancer patients who undergo a radical operation. A prospective study is warranted for further validation of our findings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467643 | PMC |
| http://dx.doi.org/10.2147/OTT.S82174 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Determination of ovarian transposition through prediction of postoperative adjuvant therapy in young patients with early stage cervical cancer undergoing surgery: a Korean multicenter retrospective study (KGOG 1042).
Obstet Gynecol Sci
May 2024
Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, Seoul, Korea.
Objective: We aimed to predict the risk of postoperative adjuvant therapy using preoperative variables in young patients with early stage cervical cancer. The predicted risk can guide whether ovarian transposition should be performed during surgery.
Methods: In total, 886 patients with stage IB1-IIA cervical cancer aged 20-45 years who underwent modified radical or radical hysterectomy between January 2000 and December 2008 were included.
The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC).
Gynecol Oncol
April 2023
Department of Obstetrics and Gynecology and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands; Department of Obstetrics and Gynecology GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands.
Introduction: One of the major changes in the revised (2018) FIGO-staging system is the addition of stage IIIC to the previously used 2009 system. We evaluated the prognostic value of positive pelvic and/or para-aortic lymph nodes in patients with cervical cancer.
Methods: A nationwide retrospective cohort study was performed by analyzing data from the Netherlands Cancer Registry.
CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEGOG-CX-05; ENGOT-CX16).
Int J Gynecol Cancer
September 2022
Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy.
Article Synopsis
- The study investigates the effectiveness of adjuvant (chemo)radiation therapy compared to radical surgery alone in patients with intermediate-risk early-stage cervical cancer.
- It aims to determine whether the addition of adjuvant treatment offers any survival benefit or if radical surgery alone is sufficient for disease-free survival.
- In this phase III trial, 514 patients will be randomly assigned to either receive no additional treatment or undergo adjuvant therapy after surgery, with patient data tracked for three to six years to assess outcomes.
Elevated Expression of Inhibitor of Apoptosis-stimulating Protein of p53 (iASPP) and Methyltransferase-like 3 (METTL3) Correlate with Poor Prognosis in FIGO Ib1-IIa Squamous Cell Cervical Cancer.
J Cancer
February 2020
Department of Radiation Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China.
: Clinical outcomes of patients with early stage cervical cancer are determined by unique molecular events. Therefore, exploring novel biomarkers for the diagnosis and prognosis of cervical cancer is essential for guidance of cervical cancer treatment. : Patients with FIGO Ib1-IIa cervical cancer who were treated with radical hysterectomy at the first affiliated hospital of Guangxi Medical University, China were included in the study.
View Article and Find Full Text PDFFertility-sparing surgery of cervical cancer >2 cm (International Federation of Gynecology and Obstetrics 2009 stage IB1-IIA) after neoadjuvant chemotherapy.
Int J Gynecol Cancer
January 2020
Gynecology, Leiden University Medical Center, Leiden, South-Holland, The Netherlands
Objective: To assess the feasibility, safety, oncological, and obstetric outcomes in patients with cervical tumors >2 cm treated with neoadjuvant chemotherapy in preparation for abdominal radical trachelectomy.
Methods: A retrospective analysis of patients with cervical cancer >2 cm (up to 6 cm) was conducted in patients who were selected to receive neoadjuvant chemotherapy before abdominal radical trachelectomy. Surgical and clinical outcomes were examined in relation to radiological and pathological results.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!